Friday, July 10, 2026

pharma · Ulcerative Colitis · Multiple Myeloma

AbbVie Deutschland GmbH

APONTIS PHARMA Deutschland is a pharma organization headquartered in Wiesbaden, DE. Primary therapeutic focus areas include Ulcerative Colitis, Multiple Myeloma, Neovascular age-related macular degeneration, Psoriatic Ar

Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
Status
Public
HQ
Wiesbaden, DE
Founded
2018
Employees
101
Programs
102
Drugs
119
Patents
23
Clinical program

Telisotuzumab Vedotin

Phase 2 · small molecule · Non-Small Cell Lung Cancer

Telisotuzumab Vedotin for Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Internal code M14-239

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AbbVie Deutschland GmbH & Co. KG
Phase
Phase 2
Modality
small_molecule
Indication
Non-Small Cell Lung Cancer
Status
active
Trials
1